EPIRUS Biopharma: Epirus files for bankruptcy protection and hands Remicade biosim to Reliance Life Sciences

Epirus Biopharmaceuticals has filed for Chapter 7 bankruptcy protection, settled with licensee Livzon Mabpharm and handed its Remicade (infliximab) biosimilar to Reliance Life Sciences (RLS).